Cercar

01/01/2022 The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
Querol L.A., Hartung H.-P., Lewis R.A., van Doorn P.A., Hammond T.R., Atassi N., Alonso-Alonso M., Dalakas M.C.. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics. 2022; 19(3)DOI:10.1007/s13311-022-01221-y. PMID:35378684. IF:5.700(Q1/2D).
01/01/2022 Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach
Mayhew A.G., James M.K., Moore U., Sutherland H., Jacobs M., Feng J., Lowes L.P., Alfano L.N., Muni Lofra R., Rufibach L.E., Rose K., Duong T., Bello L., Pedrosa-Hernández I., Holsten S., Sakamoto C., Canal A., Sánchez-Aguilera Práxedes N., Thiele S., Siener C., Vandevelde B., DeWolf B., Maron E., Gordish-Dressman H., Hilsden H., Guglieri M., Hogrel J.-Y., Blamire A.M., Carlier P.G., Spuler S., Day J.W., Jones K.J., Bharucha-Goebel D.X., Salort-Campana E., Pestronk A., Walter M.C., Paradas C., Stojkovic T., Mori-Yoshimura M., Bravver E., Díaz-Manera J., Pegoraro E., Mendell J.R., Straub V.. Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.828525. PMID:35359643. IF:3.400(Q2/5D).
01/01/2022 Predicting Outcome in Guillain-Barré Syndrome International Validation of the Modified Erasmus GBS Outcome Score
Doets A.Y., Lingsma H.F., Walgaard C., Islam B., Papri N., Davidson A., Yamagishi Y., Kusunoki S., Dimachkie M.M., Waheed W., Kolb N., Islam Z., Mohammad Q.D., Harbo T., Sindrup S.H., Chavada G., Willison H.J., Casasnovas C., Bateman K., Miller J.A.L., van den Berg B., Verboon C., Roodbol J., Leonhard S.E., Benedetti L., Kuwabara S., van den Bergh P., Monges S., Marfia G.A., Shahrizaila N., Galassi G., Péréon Y., Bürmann J., Kuitwaard K., Kleyweg R.P., Marchesoni C., Sedano Tous M.J., Querol L., Illa I., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F.H., Lehmann H.C., Granit V., Cavaletti G., Gutiérrez-Gutiérrez G., Barroso F.A., Visser L.H., Katzberg H.D., Dardiotis E., Attarian S., van der Kooi A.J., Eftimov F., Wirtz P.W., Samijn J.P.A., Jacobus Gilhuis H., Hadden R.D.M., Holt J.K.L., Sheikh K.A., Karafiath S., Vytopil M., Antonini G., Feasby T.E., Faber C.G., Gijsbers C.J., Busby M., Roberts R.C., Silvestri N.J., Fazio R., van Dijk G.W., Garssen M.P.J., Straathof C.S.M., Gorson K.C., Jacobs B.C.. Predicting Outcome in Guillain-Barré Syndrome International Validation of the Modified Erasmus GBS Outcome Score. NEUROLOGY. 2022; 98(5)DOI:10.1212/WNL.0000000000013139. PMID:34937789. IF:9.900(Q1/1D).
01/12/2025 Treatment Preferences of Neurologists in Generalized Myasthenia Gravis: A Conjoint Analysis Study
Querol, L, Gómez-Ballesteros, R, Gutierrez-Gutierrez, G, Ares, A, Villaverde, R, Reyes, V, Armangue, T, Salas, E, Diaz-Abós, P, Rebollo, P, Sarmiento, M, Canal, N, Maurino, J, Cortes-Vicente, E. Treatment Preferences of Neurologists in Generalized Myasthenia Gravis: A Conjoint Analysis Study. Neurology and Therapy. 2025; 14(6)DOI:10.1007/s40120-025-00821-y. PMID:40971137. IF:4.800(Q1/2D).